83 results
Page 3 of 5
8-K
EX-99.1
25q1al
5 Feb 21
Regulation FD Disclosure
4:27pm
8-K
EX-99.1
sk96edkabed9zut
11 Jan 21
Results of Operations and Financial Condition
8:01am
8-K
EX-1.1
oh20n9ai
20 Nov 20
Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering
4:08pm
8-K
EX-99.1
yp69k81q
12 Nov 20
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
7:40am
8-K
EX-99.1
mgjpbh7wly9q
17 Aug 20
Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors
7:46am
8-K
EX-99.1
m64v889ix ndaimgop
10 Aug 20
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
7:07am
S-3
EX-1.2
ynmqaf2vdc0x
10 Jul 20
Shelf registration
4:06pm
S-3
EX-3.2
ux6gd3bpz7 3lia
10 Jul 20
Shelf registration
4:06pm
8-K
k9l924xu uy
9 Jul 20
Regulation FD Disclosure
6:06am
8-K
EX-99.1
nagkstptsr0lx70
9 Jul 20
Regulation FD Disclosure
6:06am
8-K
EX-99.1
kq3d 00gj
15 May 20
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
7:05am
DEFA14A
eczev
21 Apr 20
Additional proxy soliciting materials
4:21pm
10-K
a5qll 15c
23 Mar 20
Annual report
4:02pm
8-K
EX-99.1
umridg
23 Mar 20
STOKE THERAPEUTICS Reports FULL YEAR 2019 financial results and provides business updateS
8:00am
424B4
p1fpyuapjym
19 Jun 19
Prospectus supplement with pricing info
4:16pm